Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 3/20 | 0.39 |
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | DAO | P14920 | 4/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2215326 | 0.76 | HTT (0.42) | HTTALDH1A1MAOBMAOACYP17A1 | |
| SCHEMBL1300421 | 0.76 | HTT (0.42) | HTTALDH1A1MAOBMAOACYP17A1 | |
| SCHEMBL29489387 | 0.75 | HTT (0.45) | HTTALDH1A1MAOBMAOACYP17A1 | |
| SCHEMBL1503157 | 0.75 | HTT (0.45) | HTTALDH1A1MAOBMAOACYP17A1 | |
| SCHEMBL12509342 | 0.74 | MAOB (0.49) | HTTALDH1A1MAOBMAOACYP17A1 | |
| SCHEMBL16105820 | 0.74 | DAO (0.55) | HTTALDH1A1MAOBMAOACYP17A1 | |
| SCHEMBL3299911 | 0.74 | CYP17A1 (0.52) | HTTALDH1A1MAOBMAOACYP17A1 | |
| SCHEMBL7974386 | 0.73 | DAO (0.42) | HTTALDH1A1MAOBMAOACYP17A1 | |
| SCHEMBL852178 | 0.72 | IDO1 (0.48) | MAOB | |
| SCHEMBL6203927 | 0.72 | HTT (0.47) | HTTALDH1A1MAOBMAOACYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210002251-A1 | Bruton's Tyrosine Kinase Inhibitors | PFIZER INC. (US) | 2021-01-07 | — | — | US | disclosed |
| US-10815213-B2 | Bruton's tyrosine kinase inhibitors | PFIZER INC. (US) | 2020-10-27 | — | — | US | disclosed |
| US-20190202798-A1 | Bruton's Tyrosine Kinase Inhibitors | PFIZER INC. (US) | 2019-07-04 | — | — | US | disclosed |
| US-10266513-B2 | Bruton's tyrosine kinase inhibitors | PFIZER INC. (US) | 2019-04-23 | — | — | US | disclosed |
| US-20170283393-A1 | Bruton's Tyrosine Kinase Inhibitors | PFIZER INC. (US) | 2017-10-05 | — | — | US | disclosed |
| EP-2914586-B1 | BRUTON'S TYROSINE KINASE INHIBITORS | PFIZER (US) | 2017-04-05 | — | — | EP | disclosed |
| US-20150291554-A1 | Bruton's Tyrosine Kinase Inhibitors | PFIZER (US) | 2015-10-15 | — | — | US | disclosed |
| EP-2914586-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | Pfizer Inc. (US) | 2015-09-09 | — | — | EP | disclosed |
| WO-2014068527-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | PFIZER INC. (US) | 2014-05-08 | — | — | WO | disclosed |
| EP-2007735-B1 | 2-SUBSTITUTED 4-BENZYLPHTHALAZINONE DERIVATIVES AS HISTAMINE H1 AND H3 ANTAGONISTS | GLAXO GROUP LTD (GB) | 2010-10-27 | — | — | EP | disclosed |
| US-20090105225-A1 | 2-Substituted 4-Benzylphthalazinone Derivatives as Histamine H1 and H3 Antagonists | GLAXO GROUP LIMITED (GB) | 2009-04-23 | — | — | US | disclosed |
| EP-2007735-A1 | 2-SUBSTITUTED 4-BENZYLPHTHALAZINONE DERIVATIVES AS HISTAMINE H1 AND H3 ANTAGONISTS | Glaxo Group Limited (GB) | 2008-12-31 | — | — | EP | disclosed |
| US-20080039444-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-02-14 | — | — | US | disclosed |
| WO-2007122156-A9 | 2-SUBSTITUTED 4-BENZYLPHTHALAZINONE DERIVATIVES AS HISTAMINE H1 AND H3 ANTAGONISTS | GLAXO GROUP LTD (GB) | 2008-01-24 | — | — | WO | disclosed |
| WO-2007122156-A1 | 2-SUBSTITUTED 4-BENZYLPHTHALAZINONE DERIVATIVES AS HISTAMINE H1 AND H3 ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10266513-B2 | Bruton's tyrosine kinase inhibitors | BTK, LCK, LYN | HTT 3429/4885ALDH1A1 4293/4885MAOB 1398/4885 |
| US-20150291554-A1 | Bruton's Tyrosine Kinase Inhibitors | BTK, LCK, LYN | HTT 3745/4885ALDH1A1 4570/4885MAOB 1212/4885 |
| US-10815213-B2 | Bruton's tyrosine kinase inhibitors | BTK, LCK, LYN | HTT 4223/4885ALDH1A1 4142/4885MAOB 1005/4885 |
| US-20210002251-A1 | Bruton's Tyrosine Kinase Inhibitors | BTK, LCK, LYN | HTT 4223/4885ALDH1A1 4142/4885MAOB 1005/4885 |
| US-20080039444-A1 | COMPOUNDS | CMA1, MRGPRX2, HRH2 | HTT 1906/4885ALDH1A1 292/4885MAOB 164/4885 |
| US-20170283393-A1 | Bruton's Tyrosine Kinase Inhibitors | BTK, LCK, LYN | HTT 3429/4885ALDH1A1 4293/4885MAOB 1398/4885 |
| US-20090105225-A1 | 2-Substituted 4-Benzylphthalazinone Derivatives as Histamine H1 and H3 Antagonists | HRH2, HRH3, HRH4 | HTT 943/4885ALDH1A1 1188/4885MAOB 696/4885 |
| US-20190202798-A1 | Bruton's Tyrosine Kinase Inhibitors | BTK, LCK, SYK | HTT 4279/4885ALDH1A1 4090/4885MAOB 956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.